<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548677</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-90091-10093</org_study_id>
    <secondary_id>2009-017485-23</secondary_id>
    <nct_id>NCT01548677</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer</brief_title>
  <acronym>TREAT-CTC</acronym>
  <official_title>TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (&quot;TREAT CTC&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SUCCESS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer
      (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating
      tumour cells (CTC) in peripheral blood.

      Eligible patients will be randomised in 1:1 ratio to either the trastuzumab arm or the
      observation arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II trial for patients with HER2 negative primary BC who after
      completing (neo) adjuvant chemotherapy and surgery have detectable CTC(s) in peripheral blood
      (see eligibility criteria for details). Eligible patients will be randomized in 1:1 ratio to
      either the trastuzumab arm or the observation arm. Patients randomized to the trastuzumab arm
      will receive a total of 6 intravenous (IV) administrations every 3 weeks (loading dose 8
      mg/kg IV and 5 cycles at 6 mg/kg every 3 weeks). Patients randomized to observation arm shall
      be observed for 18 weeks. Left ventricular ejection fraction (LVEF) assessment (MUGA and/or
      ECHO) will be done at baseline for all patients to be randomized. The next LVEF assessments
      of weeks 9 and week 18 will be done only in patients randomized to trastuzumab arm. Patient
      registered but with CTC negative result will not be followed-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTC detection</measure>
    <time_frame>18 weeks post randomisation</time_frame>
    <description>To compare circulating tumour cell (CTC)detection rate at week 18 between trastuzumab treatment arm and observational arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RFI (recurrence free interval)</measure>
    <time_frame>2 years after LPI (last patient in)</time_frame>
    <description>Recurrence Free Interval (RFI) (key secondary endpoint) between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDFS (Invasive Disease Free Survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Invasive Disease Free Survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS (disease free survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Disease Free survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Overall Survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC essay</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To evaluate in a clinical trial setting the feasibility, reliability, within patient reproducibility and variability of the assay for CTC(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC correlation</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To correlate CTC detection rate at baseline and/or week 18 with RFI, IDFS, DFS, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety (cardiac)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To assess safety, especially cardiac safety, of trastuzumab in women with HER2 negative primary tumors and CTC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1317</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <condition>Circulating Tumor Cells</condition>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.</description>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <other_name>endocrine therapy</other_name>
    <other_name>anti HER2 therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Age ≥ 18 years

          -  Written informed consent must be given according to ICH/GCP, and national/local
             regulations

          -  Availability of peripheral blood draw for CTC blood test

          -  Tumor block or minimum 10 unstained slides of 4 μm of primary tumor must be available
             prior to registration for centralized HER2 testing

          -  ER status available

          -  Adequately excised non-metastatic and non-relapsed operable primary invasive
             HER2-negative adeno-carcinoma of the breast *:

          -  the patient should have completed either

          -  adjuvant chemotherapy or

          -  neoadjuvant chemotherapy; in this case residual invasive disease in breast or lymph
             nodes is required (no complete pathological response) no further adjuvant chemotherapy
             treatment planned. Prior chemotherapy with doxorubicin restricted to a total dose of
             360 mg/m2 or with epirubicin restricted to a total dose of 720 mg/m2 is allowed

          -  No prior use of anti-HER2 therapy for any reason or immunotherapy for BC

          -  No concomitant use of bisphosphonate therapy or denosumab for any reason. Prior use of
             these agents is allowed provided that last treatment has been received at least 4
             weeks before registration in the study

          -  No prior mediastinal irradiation except internal mammary node irradiation for the
             present BC

          -  Concomitant adjuvant hormonal therapy or radiotherapy (if applicable) is allowed upon
             physician's choice

          -  The interval between definitive surgery (neoadjuvant population) or end of adjuvant
             chemotherapy (adjuvant population) and registration must be at least 3 weeks but no
             more than 24 weeks

          -  No evidence of unresolved or unstable toxicity from prior surgery, adjuvant
             chemotherapy or radiotherapy

          -  No history of prior invasive breast carcinoma, except for the BC diagnosed and treated
             before entry. Unifocal or multifocal unilateral (one breast) or unifocal or multifocal
             synchronous bilateral breast (both breasts) cancer are acceptable if all invasive
             tumor foci are HER2- negative. History of previous ductal carcinoma in situ is allowed

          -  No history of any malignant neoplasms in the past 5 years except for curatively
             treated basal and squamous cell carcinoma of the skin

          -  No prior autologous or allogeneic stem cell transplantation

          -  No history of serious cardiac illness or medical conditions, including but not
             confined to:

          -  History of documented congestive heart failure

          -  High risk uncontrolled arrhythmias

          -  Angina pectoris requiring anti-anginal medication

          -  Clinically significant valvular heart disease

          -  Evidence of transmural infarction on ECG

          -  Poorly controlled hypertension (e.g. systolic &gt; 180 mm Hg or diastolic &gt; 100 mm Hg)

          -  No history of other concurrent serious diseases that may interfere with planned
             treatment, including severe pulmonary conditions

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration

          -  WHO performance status 0-1

          -  No concurrent participation in another trial

          -  No clinically significant active infections
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michail Ignatiadis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martine Piccart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Sotiriou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves Pierga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte Rack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig-Maximilians-Universitaet Muenchen - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Innenstadt, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Jolimont</name>
      <address>
        <city>Haine St Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternité Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Léman</name>
      <address>
        <city>Contamine sur Arve</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - La Tronche - Hôpital A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles - Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mont-de-Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine De Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hopital Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Hôpitaux Universitaires de Strasbourg - Hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman - Site Georges Pianta</name>
      <address>
        <city>Thonon les Bains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valence</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Boeblingen</name>
      <address>
        <city>Boeblingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinischen Zentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Lorenz / Hecker / Wesche</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische-Hämatologischen Schwerpunktpraxis</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luisenkrankenhaus GmbH &amp; Co. KG</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum - Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev.-Luth. Diakonissenanstalt Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt Am Main-Hoechst</name>
      <address>
        <city>Frankfurt Am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-Onkologischen Schwerpunktpraxis</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Pourfard / Dr. Uleer</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Klinik GmbH Frauenklinik der St. Vincentius-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Leipzig - Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Goldmann/ Dr. Ebert</name>
      <address>
        <city>Lueneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsMedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Prof. Salat / Dr. Stötzer</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitaet Muenchen - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Innenstadt</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muencher Onkol. Praxis Elisenhof</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwaebisch-Gmuend</name>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - HELIOS Klinik Rottweil</name>
      <address>
        <city>Rottweil</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - HELIOS Brustzentrums Nordachsen - HELIOS Klinik Schkeuditz</name>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwaebisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus der Stadt Schweinfurt gGmbH</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Landkreis Sigmaringen GmbH</name>
      <address>
        <city>Sigmaringen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellschaft für onkologische Studien, Praxismanagement und -Logistik</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universitaet Tuebingen - Universitaetsfrauenklinik Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentren Rhein-Neckar - GRN-Klinik Weinheim</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Wupperta</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.eortc.be/clinicaltrials/details.asp?protocol=90091</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumour Cells</keyword>
  <keyword>HER2 negative primary breast cancer</keyword>
  <keyword>HER2 positive CTC</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

